Research Grade Lintuzumab

Catalog No.

DHD37502

Description

Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225 Ac]Ac-lintuzumab clinical trials were discussed in detail in reference . Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3

Concentration

1.39 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P20138

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

225Ac-lintuzumab, HuM195, SGN-33, SMART M195, HuM195, CAS: 166089-32-3

Clone ID

Lintuzumab

Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors, PMID: 29206680

Investigational CD33-targeted therapeutics for acute myeloid leukemia, PMID: 29534618

CD33-Targeted Therapies: Beating the Disease or Beaten to Death?, PMID: 32875599

Targeted Alpha-Particle Therapy for Hematologic Malignancies, PMID: 31253514

Targeted Alpha-Particle Therapy for Hematologic Malignancies, PMID: 32172800

Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia, PMID: 20065652

Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies, PMID: 29793418

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia, PMID: 20858843

5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia, PMID: 20495353

225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models, PMID: 33347715

Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia, PMID: 22801961

Targeted alpha-particle immunotherapy for acute myeloid leukemia, PMID: 24857092

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia, PMID: 15961759

Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial, PMID: 19557623

What happened to anti-CD33 therapy for acute myeloid leukemia?, PMID: 22109628

Newer monoclonal antibodies for hematological malignancies, PMID: 18565392

Novel drugs for older patients with acute myeloid leukemia, PMID: 25142817

Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML, PMID: 28321813

New agents: great expectations not realized, PMID: 24309529

Ab therapy of AML: native anti-CD33 Ab and drug conjugates, PMID: 17917880

Advances in immunotherapy for pediatric acute myeloid leukemia, PMID: 28945115

Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia, PMID: 25762156

Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia, PMID: 18300754

Antibody therapy for acute myeloid leukemia, PMID: 18381105

ADCs Show Promise in Leukemias, PMID: 27388473

Gateways to clinical trials, PMID: 20094643

Gateways to clinical trials, PMID: 16395422

Gateways to clinical trials, PMID: 12949633

Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands, PMID: 23014531

Precision 're'arming of CD33 antibodies, PMID: 23970353

CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A, PMID: 31439003

In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia, PMID: 27535972

Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor, PMID: 15661266

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML, PMID: 23770776

Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates, PMID: 14734685

Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia, PMID: 12141950

Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia., PMID:39955432

89Zr-immunoPET-guided selection of a CD33xIL15 fusion protein optimized for antitumor immune cell activation and in vivo tumour retention in acute myeloid leukaemia., PMID:38987489

Developing a membrane-proximal CD33-targeting CAR T cell., PMID:38772686

Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab-Auristatin Conjugate with a Wide Therapeutic Window., PMID:38561023

HuM195 and its single-chain variable fragment increase Aβ phagocytosis in microglia via elimination of CD33 inhibitory signaling., PMID:38383769

In Vitro and In Vivo Characterization of 89Zirconium-Labeled Lintuzumab Molecule., PMID:36235126

Where do we stand with radioimmunotherapy for acute myeloid leukemia?, PMID:35350938

Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab., PMID:35247915

Radiation Safety Considerations and Clinical Advantages of α-Emitting Therapy Radionuclides., PMID:34750237

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design., PMID:34531250

225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models., PMID:33347715

CD33-Targeted Therapies: Beating the Disease or Beaten to Death?, PMID:32875599

Targeted Alpha-Particle Therapy for Hematologic Malignancies., PMID:32172800

CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A., PMID:31439003

Targeted Alpha-Particle Therapy for Hematologic Malignancies., PMID:31253514

Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies., PMID:29793418

Investigational CD33-targeted therapeutics for acute myeloid leukemia., PMID:29534618

Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors., PMID:29206680

Advances in immunotherapy for pediatric acute myeloid leukemia., PMID:28945115

Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML., PMID:28321813

In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia., PMID:27535972

ADCs Show Promise in Leukemias., PMID:27388473

Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia., PMID:25762156

Novel drugs for older patients with acute myeloid leukemia., PMID:25142817

Targeted alpha-particle immunotherapy for acute myeloid leukemia., PMID:24857092

New agents: great expectations not realized., PMID:24309529

Precision 're'arming of CD33 antibodies., PMID:23970353

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML., PMID:23770776

Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands., PMID:23014531

Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia., PMID:22801961

What happened to anti-CD33 therapy for acute myeloid leukemia?, PMID:22109628

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia., PMID:20858843

5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia., PMID:20495353

Gateways to clinical trials., PMID:20094643

Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia., PMID:20065652

Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial., PMID:19557623

Newer monoclonal antibodies for hematological malignancies., PMID:18565392

Antibody therapy for acute myeloid leukemia., PMID:18381105

Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia., PMID:18300754

Ab therapy of AML: native anti-CD33 Ab and drug conjugates., PMID:17917880

Gateways to clinical trials., PMID:16395422

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia., PMID:15961759

Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor., PMID:15661266

Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates., PMID:14734685

Gateways to clinical trials., PMID:12949633

Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia., PMID:12141950

Document Download

Research Grade Lintuzumab.pdf